Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:CGON NASDAQ:PHAT NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$34.95-4.1%$40.78$16.50▼$48.45$3.26BN/A34,145 shs7,456 shsCGONCG Oncology$42.38-1.4%$32.39$14.80▼$45.56$3.23B1.31994,329 shs722,237 shsPHATPhathom Pharmaceuticals$12.36-1.4%$11.38$2.21▼$19.50$855.54M0.431.67 million shs519,717 shsTLXTelix Pharmaceuticals$9.88+3.5%$10.39$8.93▼$30.36$3.34BN/A77,377 shs67,081 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+4.32%-8.55%-9.91%-0.84%+3,644,999,900.00%CGONCG Oncology-0.67%+12.67%+28.85%+72.18%+19.04%PHATPhathom Pharmaceuticals+6.01%+7.92%+5.83%+46.72%-16.96%TLXTelix Pharmaceuticals-0.31%-6.29%+3.58%-38.57%+953,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$34.95-4.1%$40.78$16.50▼$48.45$3.26BN/A34,145 shs7,456 shsCGONCG Oncology$42.38-1.4%$32.39$14.80▼$45.56$3.23B1.31994,329 shs722,237 shsPHATPhathom Pharmaceuticals$12.36-1.4%$11.38$2.21▼$19.50$855.54M0.431.67 million shs519,717 shsTLXTelix Pharmaceuticals$9.88+3.5%$10.39$8.93▼$30.36$3.34BN/A77,377 shs67,081 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+4.32%-8.55%-9.91%-0.84%+3,644,999,900.00%CGONCG Oncology-0.67%+12.67%+28.85%+72.18%+19.04%PHATPhathom Pharmaceuticals+6.01%+7.92%+5.83%+46.72%-16.96%TLXTelix Pharmaceuticals-0.31%-6.29%+3.58%-38.57%+953,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/ACGONCG Oncology 2.79Moderate Buy$58.8238.79% UpsidePHATPhathom Pharmaceuticals 2.71Moderate Buy$17.5041.59% UpsideTLXTelix Pharmaceuticals 2.75Moderate Buy$21.00112.66% UpsideCurrent Analyst Ratings BreakdownLatest PHAT, CGON, AAPG, and TLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CGONCG OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PHATPhathom PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TLXTelix PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/7/2025CGONCG OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.0010/7/2025CGONCG OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.0010/6/2025TLXTelix PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/27/2025CGONCG OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PHATPhathom PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TLXTelix PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/26/2025CGONCG OncologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$41.00 ➝ $47.009/23/2025TLXTelix PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$23.00 ➝ $20.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$390.60M8.34N/AN/A$0.48 per share72.81CGONCG Oncology$1.14M2,834.63N/AN/A$9.63 per share4.40PHATPhathom Pharmaceuticals$55.25M15.87N/AN/A($3.71) per share-3.33TLXTelix Pharmaceuticals$516.72M6.47$0.12 per share83.81$1.12 per share8.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/ACGONCG Oncology-$88.04M-$1.77N/AN/AN/A-15,945.17%-19.37%-18.72%11/11/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%11/6/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0020.57N/AN/AN/AN/AN/ALatest PHAT, CGON, AAPG, and TLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CGONCG Oncology-$0.57N/AN/AN/A$0.07 millionN/A11/6/2025Q3 2025PHATPhathom Pharmaceuticals-$0.30N/AN/AN/A$47.03 millionN/A8/8/2025Q2 2025CGONCG Oncology-$0.49-$0.54-$0.05-$0.54$0.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International1.311.541.53CGONCG OncologyN/A22.1522.15PHATPhathom PharmaceuticalsN/A2.382.35TLXTelix PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ACGONCG Oncology26.56%PHATPhathom Pharmaceuticals99.01%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ACGONCG OncologyN/APHATPhathom Pharmaceuticals24.10%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.17 millionN/AN/ACGONCG Oncology6176.25 millionN/AOptionablePHATPhathom Pharmaceuticals11070.94 million53.85 millionOptionableTLXTelix PharmaceuticalsN/A338.44 millionN/AN/APHAT, CGON, AAPG, and TLX HeadlinesRecent News About These CompaniesTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's What Happened1 hour ago | marketbeat.comTelix Reports US$206M Revenue, FY 2025 Guidance UpgradedOctober 14 at 2:22 AM | globenewswire.comTelix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Recommendation of "Moderate Buy" from BrokeragesOctober 13 at 4:14 AM | marketbeat.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 12 at 10:24 PM | globenewswire.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXOctober 10, 2025 | prnewswire.comTelix Pharmaceuticals Issues New Securities to Bolster Strategic GrowthOctober 10, 2025 | msn.comTelix Pharmaceuticals (NASDAQ:TLX) Receives "Sell (D)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 8, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Rating Increased to Strong-Buy at Canaccord Genuity GroupOctober 8, 2025 | marketbeat.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 5, 2025 | globenewswire.comShort Interest in Telix Pharmaceuticals Limited (NASDAQ:TLX) Declines By 46.7%October 4, 2025 | marketbeat.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXOctober 3, 2025 | prnewswire.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 2, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's WhyOctober 1, 2025 | marketbeat.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 29, 2025 | globenewswire.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 28, 2025 | prnewswire.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 26, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Up 9.2% - Time to Buy?September 23, 2025 | marketbeat.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 23, 2025 | globenewswire.comCMS Grants Transitional Pass-Through Status for GozellixSeptember 23, 2025 | globenewswire.comUBS Group Issues Pessimistic Forecast for Telix Pharmaceuticals (NASDAQ:TLX) Stock PriceSeptember 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHAT, CGON, AAPG, and TLX Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$34.95 -1.50 (-4.12%) As of 12:13 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.CG Oncology NASDAQ:CGON$42.38 -0.58 (-1.35%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Phathom Pharmaceuticals NASDAQ:PHAT$12.36 -0.17 (-1.36%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Telix Pharmaceuticals NASDAQ:TLX$9.88 +0.34 (+3.51%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
